The strategic partnership aims to leverage innovative drug development revenue rights through blockchain technology and asset tokenization, marking a significant step in digital asset integration.
Hanyu Pharmaceuticals and KuCoin have officially signed a letter of intent for a strategic partnership to explore mainland China's first RWA tokenization pilot project in Hong Kong, focusing on future revenue rights from innovative drug R&D. Hanyu will utilize its expertise in GLP-1 peptide drugs, while KuCoin will provide blockchain technology and RWA solutions to support the initiative.